Nordic Labs semaglutide: the facts UK buyers need to read first

The biggest misconception: 'lab' semaglutide and pharmaceutical semaglutide are the same thing

This is the central myth worth unpacking. Nordic Labs and similar names are associated with research-chemical suppliers, sometimes marketing peptides labelled "for research use only". The semaglutide molecule may be named on the packaging, but that label is doing a lot of heavy lifting. Pharmaceutical-grade Wegovy goes through stringent manufacturing standards, batch testing, cold-chain distribution and regulatory inspection before it reaches a patient. A vial or cartridge sourced from an unlicensed supplier has had none of that. Concentration, sterility, excipients, every variable is unknown.

The MHRA has been explicit on this point. Its public guidance on GLP-1 medicines for weight loss stresses that people should only use medicines that have been prescribed by a regulated healthcare professional and dispensed by a GPhC-registered pharmacy. The agency has seized millions of doses of illegally traded weight-loss medicines and, in October 2025, raided the first UK site found to be manufacturing counterfeit tirzepatide pens. The counterfeiting problem is not theoretical. Some seized products have contained insulin rather than the labelled compound, something you would not know until you were already ill.

If you have seen Nordic Labs semaglutide listed on a website or social media, the absence of a prescription requirement is the clearest warning sign. A regulated medicine cannot be legally sold in the UK without one. You can report suspect sellers at the MHRA's Yellow Card scheme, which covers both side-effect reports and suspected counterfeit or illegal supply.

What licensed semaglutide for weight loss actually looks like in the UK

Wegovy is a once-weekly subcutaneous injection made by Novo Nordisk. The MHRA authorised it for weight management in adults with a BMI of 30 or above, or 27 and above where at least one weight-related condition is present. Treatment begins at a low dose and is increased gradually by a prescriber over several months, reaching a maintenance dose, now up to 7.2 mg following the MHRA's approval of a dedicated single-dose pen in April 2026.

The clinical evidence behind Wegovy is substantial. The STEP 1 trial, published in the New England Journal of Medicine, found an average weight reduction of around 15% over 68 weeks at the 2.4 mg dose, in adults with obesity but without type 2 diabetes. Trials at 7.2 mg have reported average losses approaching 20.7% over 72 weeks. These are headline numbers from controlled conditions; real-world results vary, and a prescriber will help you set realistic expectations.

One thing worth knowing if you are planning to start: our prescribers see a steady stream of Monday orders after people have spent the weekend reading, and payday weeks are notably busy. Orders placed before 12pm Monday to Friday, once approved, are dispatched the same day. There is no pressure to time anything perfectly, the process moves at your pace.

For a broader picture of what licensed semaglutide treatment involves, including eligibility and how the titration schedule works, the semaglutide overview page covers the detail.

Why the source of your medicine matters as much as the molecule itself

People searching for Nordic Labs semaglutide are often motivated by cost, unlicensed products are sometimes cheaper, at least on paper. But the calculation changes when you factor in what a legitimate supply chain actually provides. A prescription from a registered prescriber means someone with clinical responsibility has assessed whether semaglutide is appropriate for you, checked your medical history, and can support you if something goes wrong. That assessment is not a bureaucratic hurdle; it is the part that keeps you safe.

The cost context for Wegovy in the UK is worth understanding on its own terms. Legitimate private prescriptions include clinical assessment, the medicine itself, and ongoing support. Pricing that looks dramatically lower than the market rate for a prescription medicine is a red flag, not a bargain.

There are also legal questions for the buyer. Importing unlicensed medicines for personal use occupies a complicated legal grey area in the UK, and the MHRA's position is that medicines for human use should be authorised and obtained through the regulated supply chain. If you are uncertain about the status of a product or a seller, you can check any online pharmacy against the GPhC register at pharmacyregulation.org. A registered pharmacy will have a GPhC premises number you can verify independently.

Some people also come to this topic after reading about compounded semaglutide or products from other unregulated suppliers. Our page on Rohm Labs semaglutide covers the same regulatory landscape from a slightly different angle, if that is useful context.

How to access semaglutide legitimately through a UK prescriber

The route to licensed Wegovy in the UK is a prescription-only pathway. A prescriber reviews your health information (including BMI, relevant conditions and current medicines) and determines whether semaglutide is clinically appropriate. At nume, that review is done by a GPhC-registered Independent Prescriber on the day your consultation comes in, not by automated software. Identity and weight are verified, and your GP is notified in line with GPhC guidance.

For those who also want to understand how semaglutide compares to Nordisk's own branded product page or manufacturer information, the Nordisk Wegovy page provides that context. Similarly, if you are weighing up different semaglutide supply questions, the semaglutide labs overview looks at the broader landscape of unregulated semaglutide products in the UK and why licensed treatment differs fundamentally.

Under-18s are not eligible, and semaglutide is not recommended during pregnancy, while breastfeeding, or for those actively trying to conceive. A prescriber will go through any contraindications with you at consultation, including whether you take oral contraceptives, since some GLP-1 medicines may temporarily reduce their absorption. The weight loss treatment overview outlines the options available through nume for eligible adults.

If you have questions before you start, our FAQs page covers common ones, and our support team is available seven days a week. When you are ready to take the next step, start your free consultation and a prescriber will review your details the same day.